165 related articles for article (PubMed ID: 30158337)
1. Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS.
Tsuda M; Otani Y; Yonezawa A; Masui S; Ikemi Y; Denda M; Sato Y; Nakagawa S; Omura T; Imai S; Nakagawa T; Hayakari M; Matsubara K
Biol Pharm Bull; 2018 Nov; 41(11):1716-1721. PubMed ID: 30158337
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
[TBL] [Abstract][Full Text] [Related]
3. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
[TBL] [Abstract][Full Text] [Related]
4. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A
MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833
[TBL] [Abstract][Full Text] [Related]
5. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications.
Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V
Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805
[TBL] [Abstract][Full Text] [Related]
6. Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.
Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
Curr Pharm Biotechnol; 2018; 19(6):495-505. PubMed ID: 29968534
[TBL] [Abstract][Full Text] [Related]
7. Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product.
Saleem R; Cantin G; Wikström M; Bolton G; Kuhns S; McBride HJ; Liu J
Pharm Res; 2020 May; 37(6):114. PubMed ID: 32476063
[TBL] [Abstract][Full Text] [Related]
8. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
[TBL] [Abstract][Full Text] [Related]
9. One-month stability study of a biosimilar of infliximab (Remsima
Vieillard V; Astier A; Sauzay C; Paul M
Ann Pharm Fr; 2017 Jan; 75(1):17-29. PubMed ID: 27659414
[TBL] [Abstract][Full Text] [Related]
10. A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima.
Pisupati K; Tian Y; Okbazghi S; Benet A; Ackermann R; Ford M; Saveliev S; Hosfield CM; Urh M; Carlson E; Becker C; Tolbert TJ; Schwendeman SP; Ruotolo BT; Schwendeman A
Anal Chem; 2017 May; 89(9):4838-4846. PubMed ID: 28365979
[TBL] [Abstract][Full Text] [Related]
11. Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques.
Fang J; Doneanu C; Alley WR; Yu YQ; Beck A; Chen W
MAbs; 2016; 8(6):1021-34. PubMed ID: 27260215
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
Schellekens H; Lietzan E; Faccin F; Venema J
Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
[TBL] [Abstract][Full Text] [Related]
13. Physicochemical characterization of Remsima.
Jung SK; Lee KH; Jeon JW; Lee JW; Kwon BO; Kim YJ; Bae JS; Kim DI; Lee SY; Chang SJ
MAbs; 2014; 6(5):1163-77. PubMed ID: 25517302
[TBL] [Abstract][Full Text] [Related]
14. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.
Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y
MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062
[TBL] [Abstract][Full Text] [Related]
15. Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs.
Li W; Yang B; Zhou D; Xu J; Ke Z; Suen WC
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():57-67. PubMed ID: 27214604
[TBL] [Abstract][Full Text] [Related]
16. Regulatory Perspective of International Agencies for Development of Biosimilar Products (Monoclonal Antibodies): An Overview.
Sharma A; Khante S; Mahadik KR; Gaikwad VL
Ther Innov Regul Sci; 2020 Sep; 54(5):965-977. PubMed ID: 31933180
[TBL] [Abstract][Full Text] [Related]
17. Comparison of middle- and bottom-up mass spectrometry in forced degradation studies of bevacizumab and infliximab.
Dyck YFK; Rehm D; Winkler K; Sandig V; Jabs W; Parr MK
J Pharm Biomed Anal; 2023 Oct; 235():115596. PubMed ID: 37540995
[TBL] [Abstract][Full Text] [Related]
18. Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.
Pisupati K; Benet A; Tian Y; Okbazghi S; Kang J; Ford M; Saveliev S; Sen KI; Carlson E; Tolbert TJ; Ruotolo BT; Schwendeman SP; Schwendeman A
MAbs; 2017 Oct; 9(7):1197-1209. PubMed ID: 28787231
[TBL] [Abstract][Full Text] [Related]
19. Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS.
Harazono A; Hashii N; Kuribayashi R; Nakazawa S; Kawasaki N
J Pharm Biomed Anal; 2013 Sep; 83():65-74. PubMed ID: 23708432
[TBL] [Abstract][Full Text] [Related]
20. A review of CT-P13: an infliximab biosimilar.
McKeage K
BioDrugs; 2014 Jun; 28(3):313-21. PubMed ID: 24723086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]